logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy maps out plans for growth following £30mln deal with Yantai CIPU

Nicolas Serandour, chief executive of Advanced Oncotherapy PLC (LON:AVO), visited the Proactive Investors studio to add some extra detail to their recent announcement that they've secured £37.4mln of fresh funding - £30mln of this coming from a new Chinese investor.

The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre.

Quick facts: Advanced Oncotherapy PLC

Price: 38.145 GBX

LSE:AVO
Market: LSE
Market Cap: £93.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: VR Education's ENGAGE platform to be included in new 5G VR...

Headlines from the Proactive UK newsroom. VR Education’s (LON:VRE) Engage platform has been chosen as an embedded title in a new 5G virtual reality headset being developed by a consortium of Deutsche Telekom, Qualcomm and XRSPACE. The new headset is due to launch in...

on 4/12/19

2 min read